Peptides: Promise, Hype, and Risk

“Peptide” is not a verdict on safety.

Peptides are chains of amino acids, the building blocks of proteins. The word describes a type of molecule—not whether a treatment works, whether a product is approved, or whether its benefits outweigh its risks.

That distinction matters because very different products are being discussed under the same label. Insulin is a familiar peptide-based medicine. Specific GLP-1 medicines, including semaglutide products, have FDA-approved uses. Meanwhile, wellness sellers promote compounds such as BPC-157, TB-500, CJC-1295, and ipamorelin for recovery, body composition, or anti-aging. Evidence for an approved medicine cannot be borrowed to validate those other products. [2] [5] [7]

The useful question is not “Are peptides good or bad?” It is “Which product, for which condition, supported by which human evidence?”

Where the impact is real

Some peptide-based treatments have moved beyond symptom management toward important clinical outcomes. In 2024, the FDA approved Wegovy, a semaglutide product, to reduce the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight. That is a defined indication in a defined population—not a promise that every peptide improves longevity. [1]

These therapies also create practical questions for employer health plans: Who is clinically eligible? What support accompanies treatment? How will ongoing care be coordinated? What does coverage actually include? A meaningful clinical benefit and a challenging pharmacy budget can exist at the same time. The right response is to evaluate a treatment on its own evidence and the plan’s actual costs, rather than treating an entire molecular category as either a breakthrough or a fad.

No savings forecast follows automatically from a drug’s clinical results. Employers should distinguish outcomes demonstrated in a trial from financial outcomes demonstrated in their own covered population.

Where marketing gets ahead of the science

BPC-157: Claims about injury repair and recovery are not the same as established human benefit. One often-cited knee-pain publication was a retrospective report, not a randomized controlled trial. It cannot establish that BPC-157 reliably heals injuries, is superior to established treatment, or is safe with repeated use. [5]

TB-500: Product identity matters. Research on full-length or recombinant thymosin beta-4 should not be presented as proof for a differently formulated product or fragment marketed as TB-500. A phase I study of a specific recombinant thymosin beta-4 product provides information about that investigational product—not a blanket endorsement of wellness injections. [6]

CJC-1295 and ipamorelin: Research into growth-hormone signaling is not proof of better long-term health, safer anti-aging, or reliable performance enhancement. FDA’s CJC-1295 advisory materials concern assessment for compounding, not approval of wellness claims. Evidence for one substance also does not validate a combined “stack.” [7]

These wellness-market substances are not FDA-approved medicines. That does not mean every proposed use has been disproven; it means confident treatment claims outrun the available evidence. Animal experiments, mechanistic explanations, and testimonials cannot substitute for well-designed human trials.

The risks are more than side effects

Known drug risks. Even approved treatments require individual assessment. Semaglutide labeling describes gastrointestinal adverse effects and important warnings, including pancreatitis, gallbladder disease, and kidney injury associated with volume depletion. Its boxed warning concerns thyroid C-cell tumors observed in rodents; whether it causes these tumors in humans is unknown. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. Those are product-specific considerations, not a risk list for every peptide. [2]

Unknown long-term effects. Limited human evidence leaves important questions unanswered about repeated exposure, interactions, and effects in people with other medical conditions. “No problems reported” is not the same as safety demonstrated through adequate research.

Product quality and immune reactions. A molecule’s name on a vial does not establish purity, concentration, or sterility. FDA materials describe how peptide impurities and aggregates can contribute to immunogenicity—an immune response that may affect safety or effectiveness. Product quality is part of the clinical question, not an administrative detail. [9]

Dosing and supply-chain errors. FDA has received reports of dosing errors with compounded injectable semaglutide, some requiring hospitalization. Confusion over concentrations and measurement units contributed to errors. FDA also warns about fraudulent and improperly shipped unapproved GLP-1 products. A legitimate prescription does not make every formulation or supplier equivalent. [4] [3]

Compounded does not mean FDA-approved

Compounding can serve a legitimate patient-specific medical need. But compounded medicines do not undergo FDA’s premarket review for safety, effectiveness, and quality. FDA recommends using compounded GLP-1 drugs only when a patient’s medical needs cannot be met by an FDA-approved drug. Calling a compounded product “the same” or a “generic” does not establish equivalence. [3]

Regulatory discussions can also be misrepresented. FDA’s July 2026 compounding advisory meeting considered peptide-related substances. An advisory discussion or recommendation is not drug approval and is not, by itself, a final authorization to compound a particular product. Eligibility and enforcement conditions can change; they must be checked for the exact substance and circumstances. [8]

Likewise, “research use only” is not an assurance that a product is suitable for human treatment. A patient should not mistake a research label, a clinic’s marketing, or a certificate supplied by a seller for FDA approval.

What patients should ask

• What is the exact medication, formulation, and intended use? Is the product FDA-approved, compounded, or investigational?
• What human studies support this use, and what outcomes did they actually measure?
• What are the known risks, the unanswered questions, and the established alternatives?
• Who is prescribing it, where is it being dispensed, and who will monitor treatment and manage adverse effects?
• What will ongoing treatment involve, and what happens if it does not help?

Discuss these questions with a licensed treating clinician. FDA advises patients to obtain a prescription and use a state-licensed pharmacy for GLP-1 medicines. Do not rely on online sellers or promotional claims to make an individual treatment decision. [3]

What employers should ask

For a CFO or benefits leader, the issue is not whether to be “pro-peptide.” It is whether the plan’s pharmacy decisions are evidence-based, understandable, and financially accountable.

• Separate categories: Evaluate FDA-approved medicines by indication; do not group them with unapproved wellness offerings.
• Check coverage: Ask the plan administrator and pharmacy benefit manager about eligibility, exclusions, prior authorization, and how compounded products are handled.
• Review vendors: Request product identities, prescribing standards, pharmacy credentials, follow-up protocols, and adverse-event procedures. A wellness label should not replace clinical oversight.
• Demand measurable results: Separate clinical outcomes, utilization, and actual plan spending from testimonials or projected savings. Use appropriately aggregated information that protects employee privacy.
• Communicate carefully: Explain coverage without implying that employer sponsorship establishes a treatment’s safety. Individual care belongs with the employee’s clinician.

The bottom line

Peptide-based medicines can offer important benefits when the product, indication, and evidence align. That promise does not erase known adverse effects, and it does not validate the broader wellness market.

For patients, the priority is qualified clinical guidance and a trustworthy medication source. For employers, it is a clear distinction between established treatment and speculative claims, backed by transparent coverage decisions and meaningful oversight.

The molecule is not the business case. The evidence is.

Sources & further reading

1. FDA: Wegovy cardiovascular indication approval (2024)
2. FDA: Ozempic prescribing information (2026)
3. FDA: Concerns with unapproved GLP-1 drugs used for weight loss
4. FDA: Dosing errors with compounded injectable semaglutide
5. PubMed: BPC-157 knee-pain retrospective report
6. Peer-reviewed study: Recombinant thymosin beta-4 phase I trial
7. FDA: CJC-1295 compounding advisory committee briefing
8. FDA: July 2026 Pharmacy Compounding Advisory Committee meeting
9. FDA: Peptide immunogenicity considerations